PASTORCZAK, Agata, Andishe ATTARBASCHI, Simon BOMKEN, Arndt BORKHARDT, van der Werff ten Bosch JUTTE, Sarah ELITZUR, Andrew R GENNERY, Eva HLAVÁČKOVÁ, Arpád KEREKES, Zdenka KŘENOVÁ, Wojciech MLYNARSKI, Tomasz SZCZEPANSKI, Tessa WASSENBERG and Jan LOEFFEN. Consensus Recommendations for the Clinical Management of Hematological Malignancies in Patients with DNA Double Stranded Break Disorders. Cancers. Basel: MDPI, 2022, vol. 14, No 8, p. 1-23. ISSN 2072-6694. Available from: https://dx.doi.org/10.3390/cancers14082000.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Consensus Recommendations for the Clinical Management of Hematological Malignancies in Patients with DNA Double Stranded Break Disorders
Authors PASTORCZAK, Agata (guarantor), Andishe ATTARBASCHI, Simon BOMKEN, Arndt BORKHARDT, van der Werff ten Bosch JUTTE, Sarah ELITZUR, Andrew R GENNERY, Eva HLAVÁČKOVÁ (203 Czech Republic, belonging to the institution), Arpád KEREKES (703 Slovakia, belonging to the institution), Zdenka KŘENOVÁ (203 Czech Republic, belonging to the institution), Wojciech MLYNARSKI, Tomasz SZCZEPANSKI, Tessa WASSENBERG and Jan LOEFFEN.
Edition Cancers, Basel, MDPI, 2022, 2072-6694.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30205 Hematology
Country of publisher Switzerland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 5.200
RIV identification code RIV/00216224:14110/22:00128354
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.3390/cancers14082000
UT WoS 000786061500001
Keywords in English DNA repair disorder; Ataxia Telangiectasia; Nijmegen breakage syndrome; leukemia; lymphoma; clinical management
Tags 14110114, 14110321, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 19/2/2024 10:51.
Abstract
Simple Summary Ataxia Telangiectasia (AT) and Nijmegen breakage syndrome (NBS) are the most common DNA repair disorders (DNARDs), characterized by an exceedingly high risk for developing hematological malignancies and poor outcomes. Clinical management of lymphoproliferative diseases in AT and NBS is complicated due to the competing challenges of delivery of optimal cancer treatment and management of excessive toxicities. AT and NBS are rare genetic entities in the general population, thus gaining extensive experience in treatment of these patients is difficult. Additionally, no treatment guidelines for lymphoproliferative diseases have been specifically designed for this group of patients as yet. In this review we formulate clinical recommendations, considering the most critical aspects related to the management of lymphoproliferative disorders in AT and NBS and we concisely present the current state of knowledge about the biology and outcomes of leukemia and lymphoma in these DNARDs. Patients with double stranded DNA repair disorders (DNARDs) (Ataxia Telangiectasia (AT) and Nijmegen Breakage syndrome (NBS)) are at a very high risk for developing hematological malignancies in the first two decades of life. The most common neoplasms are T-cell lymphoblastic malignancies (T-cell ALL and T-cell LBL) and diffuse large B cell lymphoma (DLBCL). Treatment of these patients is challenging due to severe complications of the repair disorder itself (e.g., congenital defects, progressive movement disorders, immunological disturbances and progressive lung disease) and excessive toxicity resulting from chemotherapeutic treatment. Frequent complications during treatment for malignancies are deterioration of pre-existing lung disease, neurological complications, severe mucositis, life threating infections and feeding difficulties leading to significant malnutrition. These complications make modifications to commonly used treatment protocols necessary in almost all patients. Considering the rarity of DNARDs it is difficult for individual physicians to obtain sufficient experience in treating these vulnerable patients. Therefore, a team of experts assembled all available knowledge and translated this information into best available evidence-based treatment recommendations.
PrintDisplayed: 21/7/2024 07:32